Valneva Se ( (VALN) ) has released its Q4 earnings. Here is a breakdown of the information Valneva Se presented to its investors.
Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for infectious diseases, with a portfolio that includes the world’s first chikungunya vaccine.
In its full-year 2024 earnings report, Valneva SE announced a successful year, meeting its growth targets with a 13% increase in product sales and a 10% rise in total revenues compared to 2023. The company also reported a strong cash position and significant reductions in operating cash burn.
Key financial highlights include product sales reaching €163.3 million and total revenues of €169.6 million. The company reduced its net loss significantly from €101.4 million in 2023 to €12.2 million in 2024, aided by the sale of a Priority Review Voucher. Valneva also made substantial progress in its clinical and regulatory endeavors, including advancements in its Lyme disease and chikungunya vaccine programs.
Looking ahead, Valneva anticipates continued revenue growth and positive cash flows in 2025, with expectations of product sales reaching €170-180 million. The company plans to focus on strategic R&D investments while maintaining stringent cash management to support its vaccine pipeline.
Valneva’s management remains optimistic about the future, with plans to advance its science-driven pipeline and achieve key milestones, including the first Phase 3 study results for its Lyme disease vaccine candidate, VLA15, by the end of 2025.